Supporting material - Insights into the relationship between periodontitis and systemic sclerosis based on the new periodontitis classification (2018): A cross-sectional study

Supplementary Table S1. Multiple logistic regressions predicting stage III/IV or periodontitis, based on group, and adjusted for diabetes, hypertensio, and smoking status.

	OR adjusted	(95% CI)	p
Predict Stage III/IV vs Stage II/1 or no *			
Group (SSc vs. Control)	1.62	(0.73 - 3.7)	0.243
Diabetes	1.01	(0.4 - 2.65)	0.984
Hypertension	1.68	(0.81 - 3.53)	0.169
Smoker (former smoker vs. non-smoker)	1.04	(0.18 - 8.03)	0.964
Smoker (actual smoker vs. non-smoker)	1.46	(0.55 - 4.37)	0.467
Predict Periodontitis (Yes vs. No), model 1			
Group (SSc vs. Control)	2.06	(0.7 - 6.74)	0.205
Diabetes	1.38	(0.39 - 6.59)	0.643
Hypertension	2.72	(0.99 - 7.85)	0.055
Smoker (former smoker vs. non-smoker)	1.02	(0.14 - 20.98)	0.986
Smoker (actual smoker vs. non-smoker)	1.93	(0.48 - 13.05)	0.41
Predict Periodontitis (Yes vs. No), model 2 *			
Group (SSc vs. Control)	2.02	(0.7 - 6.55)	0.212
Confounding score	2.14	(1.03 - 4.78)	0.051

SSc, systemic sclerosis; OR, odds ratio; CI, confidence interval; Confounding score is the sum of points for having diabetes, hypertension, or being actual smoker; *, models without overfitting.

Supporting material - **Insights into the relationship between periodontitis and systemic sclerosis based on the new periodontitis classification (2018): A cross-sectional study**

Table S2. Systemic involvement in systemic sclerosis in relation with periodontitis severity

Stage Systemic involvement	Stage I (n=1)	Stage II (n=8)	Stage III/IV (n=38)	*p*-value
Cardiac (Yes), n (%)	0 (0)	3 (37.5)	6 (15.79)	0.334
Digestive (Yes), n (%)	1 (100)	4 (50)	24 (63.16)	0.81
Musculoskeletal	1 (100)	3 (37.5)	33 (86.84)	**0.007**
Anticentromere antibodies (A/B) (Yes), n (%)	0 (0)	3 (37.5)	15 (39.47)	1
Anti SCL70 antibodies (Yes), n (%)	1 (100)	5 (62.5)	29 (76.32)	0.562

Abbreviations: n, number; SCL70, topoisomerase type 1;

Table S3. Calprotectin and psoriasin levels in relation with the form of systemic sclerosis

Systemic sclerosis form	Diffuse (n=28)	Limited (n=21)	Difference (95% CI)	*p*-value
Calprotectin (ng/mL), median (IQR)	2.74 (2.32-3.56)	3.32 (2.19 - 4.63)	0.58 (-1.42 - 0.31)	0.174 •[n1=28,n2=21]
Psoriasin (ng/mL), median (IQR)	0.49 (0.21 - 1.06)	0.74 (0.29 - 1.24)	0.26 (-0.83 - 1.15)	0.95 •[n1=8,n2=6]

Abbreviations: CI, confidence interval; IQR, interquartile range; n, number;

Table S4. Calprotectin and psoriasin levels in relation with telangiectasia and cardiac involvement, in systemic sclerosis patients

Telangiectasia	Yes (n=35)	No (n=18)	Difference (95% CI)	p-value
Calprotectin (ng/mL), median (IQR)	2.611 (1.896 – 4.339)	3.157 (2.413 – 4.030)	0.546 (-1.134 – 0.497)	0.382•[n1=35,n2=18]
Psoriasin (pg/mL), median (IQR)	0.028 (0.028 – 0.21)	0.028 (0.028 – 0.028)	0 (0 - 0)	0.061•[n1=35,n2=18]
Cardiac involvement	Yes (n=11)	No (n=42)	Difference (95% CI)	p-value
Calprotectin (ng/mL), median (IQR)	4.215 (2.691 – 4.825)	2.744 (2.197 – 3.417)	1.471 (-0.064 – 2.128)	0.083•[n1=11,n2=42]
Psoriasin (pg/mL), median (IQR)	0.028 (0.028 – 0.028)	0.028 (0.028 – 0.067)	0 (0 - 0)	0.264•[n1=11,n2=42]

Abbreviations: CI, confidence interval; IQR, interquartile range; n, number;